<DOC>
	<DOCNO>NCT02696291</DOCNO>
	<brief_summary>The purpose study evaluate safety pharmacokinetics UV-4B oral solution administer healthy subject three time day ( TID ) 7 day .</brief_summary>
	<brief_title>Safety Pharmacokinetics UV-4B Solution Administered Orally Multiple Ascending Doses Healthy Subjects</brief_title>
	<detailed_description>This phase 1 , randomize , double-blind , placebo-controlled multiple-ascending dose study evaluate safety pharmacokinetics UV-4B oral solution administer healthy subject TID 7 day . Three cohort 8 subject ( 6 active , 2 placebo ) plan 2 additional cohort may add pending safety review initial cohort . Safety review occur cohort . Safety evaluate Day 15 basis adverse event ( AE ) monitoring , clinical laboratory testing ( hematology , serum chemistry , coagulation , urinalysis ) , vital sign , physical examination ( PE ) , electrocardiogram ( ECG ) , fecal occult blood test . Blood sample collect specified interval Day 10 pharmacokinetic assessment .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Nonsmoking , healthy male female subject age 18 45 year , inclusive . Female subject pregnant lactating . ( Female subject postmenopausal sterile ) agreement use hormonal contraception OR intrauterine device PLUS barrier contraception ( condom occlusive cap diaphragm surgical vault cap ) AND spermicidal foam/gel/cream/suppository start least 14 day first dose continue least 3 month last dose . ( Male subject ) agreement use barrier contraception sexual intercourse also refrain sperm donation first day dose 3 month last dose study product . Body weight within 60 90 kg , inclusive , body mass index 18 32 kg/mÂ² , inclusive . Agreement avoid strenuous exercise start 4 day start dose period confinement clinical unit least 96 hour followup visit . History allergy drug iminosugar class . Treatment investigational product therapy within 30 day ( 5 halflives , whichever great ) first day dose . Current past history disease/dysfunction pulmonary , cardiovascular , endocrine , hematologic , neurological , immune , gastrointestinal genitourinary , body system . Abnormalities physical examination suggestive condition may pose increase risk subject ; abnormal electrocardiogram result ( exclude benign condition ) ; Grade 1 high abnormality vital sign screen Grade 2 high abnormality vital sign checkin base modified version FDA Toxicity Grading Scale Healthy Adult Adolescent Volunteers Enrolled Preventive Vaccine Clinical Trials . Clinical laboratory test outside normal range screen Grade 2 high checkin clinical unit . Creatinine clearance &lt; 90 mL/min ( base CockcroftGault equation ) . Proteinuria great equal 1+ . Any known expect risk bleed . Scheduled surgical procedure study participation . History alcohol and/or drug abuse within 1 year prior dose and/or positive urine drug screen substance abuse screen checkin . Urine alcohol 50 mg/dL . Plasma blood donation within 30 day first day dose intention donate within 30 day final day dose . Treatment medication , either prescription nonprescription , include dietary supplement herbal medication , within 14 day dose ( within 30 day dose hepatic renal clearancealtering agent ) unable refrain medication study period . Exceptions acetaminophen ( 2 g/day ) , vitamin product recommend daily dos hormonal birth control . Positive serology test HIV antibody , hepatitis B surface antigen , hepatitis C virus antibody screen . History relevant food allergy ( ie , eggs component standard clinic meal ) unwilling comply diet restriction . Psychological and/or emotional problem would render informed consent invalid , limit ability subject comply study requirement ; Concurrent enrollment clinical trial within 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Dengue</keyword>
	<keyword>Arbovirus Infections</keyword>
	<keyword>Flaviviridae Infections</keyword>
	<keyword>Flavivirus Infections</keyword>
	<keyword>Hemorrhagic Fevers , Viral</keyword>
	<keyword>RNA Virus Infections</keyword>
	<keyword>Virus Diseases</keyword>
	<keyword>Pharmaceutical Solutions</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Therapeutic Uses</keyword>
</DOC>